Breast Cancer and Breast Health

Episodes 17-19 of 19

• 

  MinuteCE®

  Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer

  1.50 credits 10 episodes

  • 

    

    William J. Gradishar, MD

  • 

    

    Erica L. Mayer, MD, MPH

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 credits 10 episodes

• 

  RestartResume

  Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors

  RestartResume

  Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors

  MinuteCE®

  Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors

  1.50 program credits

  • 

    

    Erica L. Mayer, MD, MPH

  1.50 program credits

• 

  RestartResume

  Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC  

  RestartResume

  Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC  

  MinuteCE®

  Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC  

  1.50 program credits

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 program credits

• Previous
• 1
• 2
• Next